Riedel, Richard and Fassunke, Jana and Scheel, Andreas H. and Scheffler, Matthias and Heydt, Carina and Nogova, Lucia and Michels, Sebastian and Fischer, Rieke N. and Eisert, Anna and Scharpenseel, Heather and John, Felix and Ruge, Lea and Schaufler, Diana and Siemanowski, Janna and Ihle, Michaela A. and Wagener-Ryczek, Svenja and Pappesch, Roberto and Rehker, Jan and Bunck, Anne and Kobe, Carsten and Keil, Felix and Merkelbach-Bruse, Sabine and Buettner, Reinhard and Wolf, Juergen (2024) MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition. JOURNAL OF THORACIC ONCOLOGY, 19 (1). pp. 160-165. ISSN 1556-0864, 1556-1380
Full text not available from this repository. (Request a copy)Abstract
Introduction MET fusions have been described only rarely in NSCLC. Thus, data on patient characteristics and treatment response are limited. We here report histopathologic data, patient demographics, and treatment outcome including response to MET tyrosine kinase inhibitor (TKI) therapy in MET fusion-positive NSCLC. Methods Patients with NSCLC and MET fusions were identified mostly by RNA sequencing within the routine molecular screening program of the national Network Genomic Medicine, Germany. Results We describe a cohort of nine patients harboring MET fusions. Among these nine patients, two patients had been reported earlier. The overall frequency was 0.29% (95% confidence interval: 0.15-0.55). The tumors were exclusively adenocarcinoma. The cohort was heterogeneous in terms of age, sex, or smoking status. We saw five different fusion partner genes (KIF5B, TRIM4, ST7, PRKAR2B, and CAPZA2) and several different breakpoints. Four patients were treated with a MET TKI leading to two partial responses, one stable disease, and one progressive disease. One patient had a BRAF V600E mutation as acquired resistance mechanism. Conclusions MET fusions are very rare oncogenic driver events in NSCLC and predominantly seem in adenocarcinomas. They are heterogeneous in terms of fusion partners and breakpoints. Patients with MET fusion can benefit from MET TKI therapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Non-small cell lung cancer; MET fusion; Tyrosine kinase inhibitor resistance; MET inhibition |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Jan 2026 11:15 |
| Last Modified: | 22 Jan 2026 11:15 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65130 |
Actions (login required)
 |
View Item |
